Carvedilol protects against lethal reperfusion injury through antiadrenergic mechanisms

Journal of Cardiovascular Pharmacology

Volumn 28, Issue 3, 1996, Pages 409-417

  Brunvand, Harald ^a,b   Kvitting, Peder M ^a   Rynning, Stein Erik ^a   Berge, Rolf K ^b   Grong, Ketil ^a  

^a Department of Surgery   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Adrenergic receptor blockade; Carvedilol; Myocardial ischemia; Reperfusion injury

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DOXAZOSIN; PROPRANOLOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAT; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; HEART INFARCTION SIZE; HEART MUSCLE BLOOD FLOW; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART VENTRICLE FIBRILLATION; MALE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY;

ADRENERGIC ANTAGONISTS; ANIMALS; CARBAZOLES; CATS; DOXAZOSIN; FREE RADICAL SCAVENGERS; GLUTATHIONE; HEART; HEMODYNAMIC PROCESSES; MALE; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PROPANOLAMINES; PROPRANOLOL; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 0029824704     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199609000-00010     Document Type: Article

References (38)

1. Reimer KA, Vander Heide RS, Richard VJ. Reperfusion in acute myocardial infarction: effect of timing and modulating factors in experimental models. Am J Cardiol 1993;72: 13G-21G.
2. Becker LC, Ambrosio G. Myocardial consequences of reperfusion. Prog Cardiovasc Dis 1987;30:23-44.
3. Simpson PJ, Lucchesi BR. Free radical and myocardial ischemia and reperfusion injury. J Lab Clin Med 1987;110: 13-30.
4. Engler R, Gilpin E. Can Superoxide dismutase alter myocardial infarct size? Circulation 1989;79:1137-42.
5. Kloner RA. Does reperfusion injury exist in humans? J Am Coll Cardiol 1993;21:537-45.
6. Zahger D, Yano J, Chaux A, Fishbein MC, Ganz W. Absence of lethal reperfusion injury after 3 hours of reperfusion: a study in a single-canine-heart model of ischemia-reperfusion. Circulation 1995;91:2989-94.
7. Bolli R. Oxygen-derived free radicals and myocardial reperfusion injury: an overview, Cardiovasc Drugs Ther 1991;5: 249-68.
8. Willerson JT, Buja M. Protection of the myocardium during myocardial infarction: pharmacologic protection during thrombolytic therapy. Am J Cardiol 1990;65:351-411.
9. Jeroudi MO, Hartley CJ, Bolli R. Myocardial reperfusion injury: role of oxygen radicals and potential therapy with antioxidants. Am J Cardiol 1994;73:2B-7B.
10. Schlack W, Uebing A, Schäfer M, et al. Regional contractile blockade at the onset of reperfusion reduces infarct size in the dog heart. Pflugers Arch 1994;428:134-41.
11. Schlack W, Uebing A, Schäfer M. et al. Intracoronary SINIC during reperfusion reduces infarct size in dog. J Cardiovasc Pharmacol 1995;25:424-31.
12. Pitarys II CJ, Virmani R, Vildibill HD Jr, Jackson EK, Forman MB. Reduction of myocardial reperfusion injury by intravenous adenosine administered during the early reperfusion period. Circulation 1991;83:237-47.
13. Litt MR, Jeremy RW, Weisman HF, Winkelstein JA, Becker LC. Neutrophil depletion limited to reperfusion reduces myocardial infarct size after 90 minutes of ischemia. Evidence for neutrophil-mediated reperfusion injury. Circulation 1989;80:1816-27.
14. 1-adrenergic system and arrhythmias in ischemic heart disease. Eur Heart J 1991;12(suppl F):88-98.
15. Nichols AJ, Sulpizio AC, Ashton DJ, Hieble JP, Ruffolo RR Jr. In vitro pharmacologic profile of the novel beta-adrenoceptor antagonist and vasodilator, carvedilol. Pharmacology 1989;39:327-36.
16. 1,-adrenoceptors. Chirality 1989;1:265-70.
17. Nichols AJ, Gellai M, Ruffolo RR Jr. Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol. Fund Clin Pharmacol 1991;5: 25-38.
18. Yue TL, Liu T, Feuerstein GZ. Carvedilol, a new vasodilator and β-adrenoceptor antagonist, inhibits oxygen-radical-mediated lipid peroxidation in swine ventricular membranes. Pharmacol Commun 1992;1:27-35.
19. Feuerstein GZ, Yue TL, Cheng HY, Ruffolo RR Jr. Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity. J Hypertens 1993:11(suppl 4):S41-8.
20. Yue TL, Mckenna PJ, Gu JL, Cheng HY, Ruffolo RR Jr, Feuerstein GZ. Carvedilol, a new antihypertensive agent, prevents lipid peroxidation and oxidative injury to endothelial cells. Hypertension 1993;22:922-8.
21. Feuerstein GZ, Hamburger SA, Smith III EF, Bril A, Ruffolo RR Jr. Myocardial protection with carvedilol. J Cardiovasc Pharmacol 1992;19(suppl 1):S138-41
22. Hamburger SA, Barone FC, Feuerstein GZ, Ruffolo RR Jr. Carvedilol (Kredex®) reduces infarct size in a canine model of acute myocardial infarction. Pharmacology 1991;43: 113-20.
23. Bril A, Slivjak M, DiMartino MJ, et al. Cardioprotective effects of carvedilol, a novel β-adrenoceptor antagonist with vasodilating properties, in anaesthetised minipigs: comparison with propranolol. Cardiovasc Res 1992;26:518-25.
24. Brunvand H, Rynning SE, Hexeberg E, Westby J, Grong K. Non-uniform recovery of segment shortening during reperfusion following regional myocardial ischemia despite uniform recovery of ATP. Cardiovasc Res 1995;30:138-46.
25. Hexeberg E, Matre K, Birkeland S, Lekven J. Non-uniform shortening of the anterior wall of feline left ventricles. Am J Physiol 1989;257:H1165-73.
26. Hexeberg E, Matre K, Lekven J. Transmural fiber direction in the anterior wall of the feline left ventricle; theoretical considerations with regard to uniformity of contraction. Acta Physiol Scand 1991;141-.497-505.
27. 1-adrenergic blockade influence regional blood flow regulation in hearts with coronary artery occlusion? Clin Physiol 1989;9:107-20.
28. Svardal AM, Mansoor MA, Ueland PM. Determination of reduced, oxidized, and protein-bound glutathione in human plasma with precolumn derivatization with monobromobimane and liquid chromatography. Anal Biochem 1990;184: 338-46.
29. Li X-Y, Chow CK. An improved method for the measurement of malondialdehyde in biological samples. Lipids 1994; 29:73-5.
30. Heyman MA, Payne BD, Hoffmann JIE, Rudolph AM. Blood flow measurements with radionuclide-labeled particles. Prog Cardiovasc Dis 1977;20:55-79.
31. Abel FL. Maximal negative dP/dt as an indicator of end of systole. Am J Physiol 1981;240:H676-9.
32. Strasser RH, Marquetant R, Kübler W. Adrenergic receptor and sensitization of adenylyl cyclase in acute myocardial ischemia. Circulation 1990;82(suppl II):1123-9.
33. Ruffolo RR Jr, Boyle DA, Brooks DP, et al. Carvedilol: a novel cardiovascular drug with multiple actions. Cardiovasc Drug Rev 1992;10:127-57.
34. Takeo S, Liu J-X, Tanonaka K, et al. Reperfusion at reduced flow rates enhances postischemic contractile recovery of perfused heart. Am J Physiol 1995;268:H2384-95.
35. Dikshit M, Rastogi L, Shukla R, Srimal RC. Prevention of ischaemia-induced biochemical changes by curcumin & quinidine in the cat heart. Indian J Med Res 1995;101:31-5.
36. Birkeland S, Westby J, Hessevik I, Grong K, Hexeberg E, Lekven J. Compensatory subendocardial hyperkinesis in the cat is abolished during coronary insufficiency outside an acutely ischaemic region. Cardiovasc Res 1992;26:285-91.
37. Birkeland S, Westby J, Grong K, Hexeberg E, Lekven J. Compensatory regional contraction following coronary artery occlusion depends on subendocardial hyperaemia and hyperkinesis. Eur Heart J 1992;13:1207-16.
38. Hexeberg E, Birkeland S, Grong K, Matre K, Lekven J. Coronary artery stenosis provokes non-uniformity of two-dimensional deformation in the anterior wall of the feline left ventricle. Eur Heart J 1992;13:981-9.